Patent
Xspray Pharma settles with BMS over Sprycel generic, awaits FDA nod
Anika Sharma
Xspray Pharma, which encountered an FDA setback in July, was initially aiming to launch its competitor to Bristol Myers Squibb’s ...
Cabometyx patent battle is resolved by Exelixis and Teva with a 2031 generic license
SG Tylor
Source – Exelixis Exelixis, the company behind the successful cancer drug Cabometyx, has been actively defending its intellectual property. In ...
Novartis to Appeal Court Decision on Entresto Combination Patent; Confirms 2023 Guidance and Mid-Term Outlook
SG Tylor
Source: Novartis On July 7, 2023, Novartis received a negative decision from the US District Court regarding the validity of ...
Another Stelara patent settlement was reached by J&J, this time with Alvotech and Teva
SG Tylor
Source – Johnson & Johnson By early 2025, a new settlement may allow for the entry of a second biosimilar ...
Astellas Faces Setback in the US Patent Trial for Myrbetriq
SG Tylor
Source – Astellas An important patent that Astellas has on the urinary incontinence medicine Myrbetriq has been declared invalid by ...
